Amphastar Pharmaceuticals, Inc.
AMPHNASDAQHealthcare● Active
$19.41
$-0.33(-1.67%)
Market Cap$855843551
P/E Ratio—
52W High$31.26
52W Low$16.65
Amphastar Pharmaceuticals, Inc. (AMPH) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AMPH · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$0.42
Est. $0.70 · -40.0%
Revenue
$0.17B
Est. $0.17B · -1.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
AMPH reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $0.64 | — | — | — | $0.18B | — |
| ▼ Q2 FY2026 | May 7, 2026 | $0.70 | $0.42 | -40.0% | $0.17B | $0.17B | -1.3% |
| ▼ Q1 FY2026 | Feb 26, 2026 | $0.90 | $0.73 | -19.2% | $0.18B | $0.19B | -3.0% |
| ▲ Q4 FY2025 | Nov 6, 2025 | $0.77 | $0.93 | +20.8% | $0.19B | $0.19B | +0.7% |
| ▲ Q3 FY2025 | Aug 7, 2025 | $0.71 | $0.85 | +19.7% | $0.17B | $0.18B | -1.5% |
| ▲ Q2 FY2025 | May 7, 2025 | $0.66 | $0.74 | +12.1% | $0.17B | $0.17B | -1.5% |
| ▼ Q1 FY2025 | Feb 27, 2025 | $1.01 | $0.92 | -8.9% | $0.19B | $0.19B | -1.2% |
| ▼ Q4 FY2024 | Nov 6, 2024 | $0.99 | $0.96 | -3.0% | $0.19B | $0.19B | -1.7% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$0.64
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
$0.42
EPS Est.
$0.70
EPS Surpr.
-40.0%
Revenue
$0.17B
Q1 FY2026
Feb 26, 2026Miss
EPS Actual
$0.73
EPS Est.
$0.90
EPS Surpr.
-19.2%
Revenue
$0.18B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
$0.93
EPS Est.
$0.77
EPS Surpr.
+20.8%
Revenue
$0.19B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
$0.85
EPS Est.
$0.71
EPS Surpr.
+19.7%
Revenue
$0.17B
Q2 FY2025
May 7, 2025Beat
EPS Actual
$0.74
EPS Est.
$0.66
EPS Surpr.
+12.1%
Revenue
$0.17B
Q1 FY2025
Feb 27, 2025Miss
EPS Actual
$0.92
EPS Est.
$1.01
EPS Surpr.
-8.9%
Revenue
$0.19B
Q4 FY2024
Nov 6, 2024Miss
EPS Actual
$0.96
EPS Est.
$0.99
EPS Surpr.
-3.0%
Revenue
$0.19B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.77 | $0.81 | $0.85 | 2 |
| Q3 FY2027 | $0.78 | $0.82 | $0.86 | 1 |
| Q2 FY2027 | $0.65 | $0.68 | $0.71 | 1 |
| Q1 FY2027 | $0.60 | $0.63 | $0.66 | 2 |
| Q4 FY2026 | $0.78 | $0.82 | $0.86 | 2 |
| Q3 FY2026 | $0.72 | $0.81 | $0.90 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 3 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q2 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q1 FY2027 | $0.2B | $0.2B | $0.2B | 3 |
| Q4 FY2026 | $0.2B | $0.2B | $0.2B | 3 |
| Q3 FY2026 | $0.2B | $0.2B | $0.2B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -40.0% | $23.90 | $24.03 | +0.54% |
| ▼ Q1 FY2026 | Feb 26, 2026 | -19.2% | $27.97 | $26.49 | -5.29% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +20.8% | $25.31 | $24.23 | -4.27% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +19.7% | $20.82 | $21.62 | +3.84% |
| ▲ Q2 FY2025 | May 7, 2025 | +12.1% | $23.87 | $24.43 | +2.35% |
| ▼ Q1 FY2025 | Feb 27, 2025 | -8.9% | $31.21 | $31.49 | +0.90% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -3.0% | $51.56 | $53.40 | +3.57% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +22.1% | $39.40 | $38.89 | -1.29% |
Q2 FY2026+0.54%
Report Date
May 7, 2026
EPS Beat/Miss
-40.0%
Price Before
$23.90
Price After
$24.03
Q1 FY2026-5.29%
Report Date
Feb 26, 2026
EPS Beat/Miss
-19.2%
Price Before
$27.97
Price After
$26.49
Q4 FY2025-4.27%
Report Date
Nov 6, 2025
EPS Beat/Miss
+20.8%
Price Before
$25.31
Price After
$24.23
Q3 FY2025+3.84%
Report Date
Aug 7, 2025
EPS Beat/Miss
+19.7%
Price Before
$20.82
Price After
$21.62
Q2 FY2025+2.35%
Report Date
May 7, 2025
EPS Beat/Miss
+12.1%
Price Before
$23.87
Price After
$24.43
Q1 FY2025+0.90%
Report Date
Feb 27, 2025
EPS Beat/Miss
-8.9%
Price Before
$31.21
Price After
$31.49
Q4 FY2024+3.57%
Report Date
Nov 6, 2024
EPS Beat/Miss
-3.0%
Price Before
$51.56
Price After
$53.40
Q3 FY2024-1.29%
Report Date
Aug 7, 2024
EPS Beat/Miss
+22.1%
Price Before
$39.40
Price After
$38.89
Avg Beat Reaction+0.16%
Avg Miss Reaction-0.07%
Beat Rate4 / 8 quarters
Largest Move-5.29% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AMPH ends December
Amphastar Pharmaceuticals, Inc. (AMPH) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $0.42 — missing the analyst consensus of $0.70 by -40.0%. The next AMPH earnings date is expected around September 1, 2026.
Each quarter, investors track AMPH earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AMPH revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AMPH's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AMPH earnings · 5 questionsAmphastar Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. AMPH typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AMPH historically reports after market close (AMC).
AMPH earnings datewhen is AMPH earningsAMPH next earnings datewhen does AMPH report earningsAMPH earnings calendar
▸ Source: FMP · Amphastar Pharmaceuticals, Inc. SEC filings · US GAAP · Amphastar Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026